One of the falling biotech stocks ADMA Biologics, today jumps 70% in premarket on over 900k shares. Since November 10th of 2014 ADMA has fallen from $12.45 and now it reaches $4.20.
ADMA Biologics rarely informs clinical and preclinical trials to alarm the investors who seek any news from the business world. Investor relations are crucial now to maintain a good image in the stock market.
Below $5 stock is usually a target for any trader with an intention to hold long or short to take a quick margin. Due to little negative EPS receiving dividends is possible to common shareholders as sometimes quarterly earnings may beat expectations.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.